Payment overview · 2025
General Payments
$712.47
25 reported records · 8 companies
Healthcare provider profile · identity verified
William Thomas Rawlinson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GERMANTOWN, TN · NPI 1013015635
Verified facts
What the public records show
CMS Open Payments records show William Thomas Rawlinson, MD received $712.47 in general payments during 2025 across 25 reported records.
Lilly USA, LLC accounted for 43.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $312.80 | 43.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.90 | 20.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $103.88 | 14.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.32 | 7.8% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $32.65 | 4.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $27.02 | 3.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.71 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.19 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $712.47 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $195.59 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.90 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $103.88 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $103.88 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.07 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.34 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.32 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $32.65 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 726 | 210 |
| Gabapentin | Gabapentin | 526 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 120 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 406 | 69 |
| Alprazolam | Alprazolam | 356 | 59 |
| Losartan Potassium | Losartan Potassium | 276 | 81 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 273 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 82 |
| Potassium Chloride | Potassium Chloride | 259 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 89 |
| Metformin Hcl Er | Metformin Hcl | 239 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 237 | 73 |
| Jardiance | Empagliflozin | 217 | 56 |
| Montelukast Sodium | Montelukast Sodium | 211 | 60 |
| Metformin Hcl | Metformin Hcl | 186 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 57 |
| Omeprazole | Omeprazole | 165 | 49 |
| Furosemide | Furosemide | 158 | 46 |
| Lorazepam | Lorazepam | 156 | 30 |
| Meloxicam | Meloxicam | 152 | 39 |
| Carvedilol | Carvedilol | 151 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 26 |
| Simvastatin | Simvastatin | 145 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 57 |
| Eliquis | Apixaban | 139 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 22 |
| Tramadol Hcl | Tramadol Hcl | 132 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 34 |
| Lisinopril | Lisinopril | 125 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 32 |
| Celecoxib | Celecoxib | 110 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 28 |
| Clonazepam | Clonazepam | 99 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 99 | 29 |
| Allopurinol | Allopurinol | 93 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 31 |
| Ozempic | Semaglutide | 93 | 18 |
| Sertraline Hcl | Sertraline Hcl | 82 | 20 |
| Pregabalin | Pregabalin | 80 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 76 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 26 |
| Xarelto | Rivaroxaban | 75 | 14 |
| Terazosin Hcl | Terazosin Hcl | 72 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 21 |
| Famotidine | Famotidine | 69 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 13 |
| Linzess | Linaclotide | 68 | 15 |
| Atenolol | Atenolol | 65 | 16 |
| Donepezil Hcl | Donepezil Hcl | 65 | 20 |
| Methylprednisolone | Methylprednisolone | 64 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 19 |
| Ezetimibe | Ezetimibe | 59 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 53 | 15 |
| Cefdinir | Cefdinir | 50 | 47 |
| Indapamide | Indapamide | 49 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 14 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | 11 |
| Trazodone Hcl | Trazodone Hcl | 42 | 15 |
| Valsartan | Valsartan | 42 | 13 |
| Diazepam | Diazepam | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 14 |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | 14 |
| Fenofibrate | Fenofibrate | 38 | 12 |
| Mirtazapine | Mirtazapine | 38 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Finasteride | Finasteride | 37 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 21 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 27 |
| Ketoconazole | Ketoconazole | 28 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 22 |
| Baclofen | Baclofen | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 12 |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Felodipine Er | Felodipine | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Cefadroxil | Cefadroxil | 21 | 20 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Lumigan | Bimatoprost | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Prednisone | Prednisone | 13 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $712.47 · 25 records | Lilly USA, LLC | Dexcom G6 Transmitter, GVOKE HYPOPEN, Kerendia, MOUNJARO, NUPLAZID, OTEZLA, Ozempic, REPATHA, Rybelsus, XYOSTED, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error